Pharmaceutical company, Pfizer, has announced that the UK's first self-injectable contraceptive for women is now available for use at home.
The Sayana Press long-acting reversible contraceptive has received a licence which means women can inject themselves at home, instead of having to go to their GP or clinic. The Medicines and Healthcare Products Regulatory Agency (MHRA) has extended the label for the product. Each jab provides contraception for at least 13 weeks. Women will need to see a healthcare professional for training but can then administer Sayana at home, although they will still be called for yearly check-ups. In response to the news, Genevieve Edwards, Director of Policy at Marie Stopes UK, said
“We’ve found that being able to self-inject is very popular with women living in remote communities around the world who find it difficult to get to a clinic four times a year. It may have a similar appeal for women in the UK who’d rather inject at home and have annual check-ups, and if it frees up precious time for nurses and doctors, that can only be a good thing.
“There are now more ways for women to manage their fertility than ever before, and yet the contraceptive pill remains by far the most usually prescribed method, despite not necessarily being the most effective. This development serves as a useful reminder to women to explore all the options available to them – it’s highly likely there’s a method available that’s better suited to your life stage and life style.”Back to news